secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0000882095-24-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q4 revenue $7.1B (-4% YoY); FY23 non-GAAP EPS $6.72; guides FY24 product sales $27.1-27.5B
--------------------------------------------------------------------------------

- Q4 2023 GAAP EPS $1.14 (down from $1.30); non-GAAP EPS $1.72 (up from $1.67).
- Full-year 2023 product sales $26.9B, flat YoY; HIV sales up 6% to $18.2B; Biktarvy up 14% to $11.8B.
- Oncology sales up 37% for full year; Cell Therapy $1.9B (+28%); Trodelvy $1.1B (+56%).
- Veklury sales fell 44% to $2.2B in FY23; Q4 Veklury $720M (-28% YoY).
- FY24 guidance: product sales $27.1-27.5B, Veklury ~$1.3B, GAAP EPS $5.15-5.55, non-GAAP EPS $6.85-7.25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209524000003/0000882095-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209524000003/gild-20240206.htm
  HTML page:      https://secwatch.observer/filing/0000882095-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer